Expectations trend
FY2028 · fiscal year ending 2028-09-30 · fmp
$-0.69 → $-0.46 · observed estimates
Veru Inc (VERU)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$2.06-6.36%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for VERU yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
EPS improves to near -$0.26 per share | The company targets EPS near -$0.26 per share in 2026, improving from prior losses. | Improving | EPS remains below -0.26 USD per share in FY26 | Diluted EPS: $-0.30 per share FY2026-Q3; GAAP. Published target: EPS >= -0.26 USD per share. Annual target cannot be compared with a quarterly or TTM observation. Aug 10, 2026-0.3 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-09-30 · fmp
$-0.69 → $-0.46 · observed estimates
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Dec 16, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-development company, not a profitable compounder. Its current long-term thesis is in a watch state: trial enrollment and study progress are on track, but recent financial performance remains weak and risk is high.
The valuation model indicates VERU is expensive versus peers, with a sizable expectations gap, though confidence in that estimate is low. The evidence does not show that weak fundamentals and turbulence are fully reflected in expectations, so the priced-in picture is uncertain.
Near term, losses and operating performance may remain uneven: operating loss and net loss both increased in 2026-Q3 after improving earlier. Management completed enrollment in the Phase 2b PLATEAU trial ahead of its target and expects interim results in Q1 2027, but the next financial update carries elevated miss risk.
The multi-year case depends on trial results, continued progress in enobosarm intellectual-property protection, and whether losses begin to improve consistently. Near term, a guidance cut would be a negative signal, while stronger results and guidance from large healthcare companies could support the sector backdrop.
Over the next 1 to 3 years, VERU remains a high-risk clinical-development thesis with credible trial progress but limited evidence of financial improvement. The evidence is mixed, and the key test is whether clinical milestones translate into stronger fundamentals. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Debt issuances provide liquidity for clinical development. |
| Improving |
| No sufficient debt issuance or liquidity to fund operations through FY26 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Operating income improves | is improving its operating income as shown in recent earnings beats. | Intact | Operating income fails to improve over next 4 quarters | Operating income: $-7.714M FY2026-Q3; GAAP. Published target: Operating income improves over prior quarters. Target period is not explicitly aligned with this observation. Aug 10, 2026-7,713,681 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.05B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-10-01 | $-0.69 | $50,000,000 | 2 / 1 |
| 2026-10-02 | $-0.69 | $50,000,000 | 2 / 1 |
| 2026-10-03 | $-0.69 | $50,000,000 | 2 / 1 |
| 2026-10-04 | $-0.69 | $50,000,000 | 2 / 1 |
| 2026-10-05 | $-0.69 | $50,000,000 | 2 / 1 |
| 2026-10-06 | $-0.69 | $50,000,000 | 2 / 1 |
| 2026-10-07 | $-0.69 | $50,000,000 | 2 / 1 |
| 2026-10-08 | $-0.69 | $50,000,000 | 2 / 1 |
| 2026-10-09 | $-0.46 | $12,500,000 | 2 / 1 |
| 2026-10-10 | $-0.46 | $12,500,000 | 2 / 1 |
| 2026-10-11 | $-0.46 | $12,500,000 | 2 / 1 |
| 2026-10-12 | $-0.46 | $12,500,000 | 2 / 1 |
| 2026-10-13 | $-0.46 | $12,500,000 | 2 / 1 |
| 2026-10-14 | $-0.46 | $12,500,000 | 2 / 1 |
| 2026-10-15 | $-0.46 | $12,500,000 | 2 / 1 |
| 2026-10-16 | $-0.46 | $12,500,000 | 2 / 1 |
| 2026-10-17 | $-0.46 | $12,500,000 | 2 / 1 |
| 2026-10-18 | $-0.46 | $12,500,000 | 2 / 1 |
| 2026-10-19 | $-0.46 | $12,500,000 | 2 / 1 |
| 2026-10-20 | $-0.46 | $12,500,000 | 2 / 1 |
| 2026-10-21 | $-0.46 | $12,500,000 | 2 / 1 |
| 2026-10-22 | $-0.46 | $12,500,000 | 2 / 1 |
| 2026-10-23 | $-0.46 | $12,500,000 | 2 / 1 |
| 2026-10-24 | $-0.46 | $12,500,000 | 2 / 1 |
| 2026-10-25 | $-0.46 | $12,500,000 | 2 / 1 |
| 2026-10-26 | $-0.46 | $12,500,000 | 2 / 1 |
| 2026-10-27 | $-0.46 | $12,500,000 | 2 / 1 |
| 2026-10-28 | $-0.46 | $12,500,000 | 2 / 1 |
| 2026-10-29 | $-0.46 | $12,500,000 | 2 / 1 |
| 2026-10-30 | $-0.46 | $12,500,000 | 2 / 1 |
| 2026-10-31 | $-0.46 | $12,500,000 | 2 / 1 |
| 2026-11-01 | $-0.46 | $12,500,000 | 2 / 1 |
| 2026-11-02 | $-0.46 | $12,500,000 | 2 / 1 |
| 2026-11-03 | $-0.46 | $12,500,000 | 2 / 1 |
| 2026-11-04 | $-0.46 | $12,500,000 | 2 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 3 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.